Scientific Program Committee

CROI 2008 Session 25
k Tuesday, 10-11:30 am; Auditorium
CME
Session 23–Oral Abstracts
HIV Vaccines
Moderators:
John Mellors, Univ of Pittsburgh, PA, US
Mario Stevenson, Univ of Massachusetts Med Sch, Worcester, US
10:00 85 GeoVax Clade B DNA/MVA HIV/AIDS Vaccine Is
Well Tolerated and Immunogenic when Administered
to Healthy Seronegative Adults (HVTN 065 part A)
Harriet Robinson* 1 , P Goepfert2 , C Hay3 , S Frey4 , W Blattner5 ,
P Wright6 , M Elizaga7 , L Qin7 , B Moss8 , and HVTN 065 Protocol Team
1 2 GeoVax Inc, Atlanta, GA, US; Univ of Alabama at Birmingham,
US; 3Univ of Rochester, NY, US; 4St Louis Univ, MO, US; 5Inst of
Human Virology, Univ of Maryland, Baltimore, US; 6Vanderbilt Univ, Nashville, TN, US; 7Fred Hutchinson Cancer Res Ctr, Seattle,
WA, US; and 8NIAID, NIH, Bethesda, MD, US
10:15 86 Cellular Immune Responses in HIV-1 Uninfected
Adult Tanzanian Volunteers Enrolled in a Phase I/
II Multiclade HIV-1 DNA Plasmid Vaccine (VRC-
HIVDNA016-00-VP)/Adenovirus-5 Vector (VRC-
HIVADV014-00-VP) Boost Vaccine Trial
Alexandra Schuetz* 1,2 , A Haule1 , M Schunk1 , L Maboko1 ,
M Hoelscher1 , M Robb2 , N Michael2 , B Graham3 , J Cox2 , and
M de Souza2,4 1 2 Mbeya Med Res Prgm, Tanzania; US Military HIV Res Prgm,
Rockville, MD, US; 3Vaccine Res Ctr, NIAID, NIH, Bethesda, MD,
US; and 4Armed Forces Res Inst of Med Sci, Bangkok, Thailand
10:30 87 Therapeutic Vaccination with a Replication Defective
Adenovirus Type 5 HIV-1 gag Vaccine in a Prospective,
Double-blinded, Placebo-controlled Trial (ACTG 5197)
Robert Schooley* 1 , H Wang2 , J Spritzler2 , M Lederman3 , D Havlir4 ,
D Kuritzkes5 , C Battaglia6 , C Godfrey7 , M Robertson8 , B Schock9 ,
and AIDS Clinical Trials Group
1 2 Univ of California, San Diego, US; Harvard Sch of Publ Hlth,
Boston, MA, US; 3Case Western Reserve Univ, Cleveland, OH,
US; 4Univ of California, San Francisco, US; 5Partners Hlthcare,
Boston, MA, US; 6Social & Sci Systems, Silver Spring, MD, US; 7Div of AIDS, NIAID, NIH, Bethesda, MD, US; 8Merck Res Labs, North
Wales, PA, US; and 9Frontier Sci and Tech Res Fndn, Amherst,
NY, US
10:45 88LB Efficacy Results from the STEP Study (Merck V520
Protocol 023/HVTN 502): A Phase II Test-of-Concept
Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent
Vaccine
M Robertson1 , D Mehrotra1 , D Fitzgerald2 , A Duerr3 , D Casimiro1 ,
J McElrath3 , D Lawrence4 and Susan Buchbinder* 5
1 2 Merck Res Labs, West Point, PA, US, GHESKIO, Port-au-Prince,
Haiti; 3HIV Vaccine Trials Network, Seattle, WA, US; 4NIAID, NIH,
Bethesda, MD, US; and 5San Francisco Dept of Publ Hlth, CA, US
11:05 89LB Immunological Characterization of Subjects from the
STEP Study: A Phase IIB Test-of-Concept Trial of the
MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine
Michael Robertson* 1 , D Casimiro1 , S De Rosa2 , S Dubey1 , L
Kierstead1 , and J McElrath2 1 2 Merck Res Labs, West Point, PA, US and Fred Hutchinson Cancer
Res Ctr, HIV Vaccine Trials Network, Seattle, WA, US
l Tuesday, 11:30 am-12 noon; Auditorium
Session 24–Plenary CME
Scientific Obstacles to an Effective HIV Vaccine
91
Ronald Desrosiers
New England Primate Res Ctr, Harvard Med Sch, Boston,
MA, US
Objectives: This session is directed to clinicians, scientists, and administrators
interested in the development of a safe, effective, preventive vaccine for
HIV-1. It is assumed that participants are familiar with the fundamentals
of immunology and the historic role of vaccines in limiting the spread of
viral disease. At the completion of the session, participants will have gained
knowledge of the formidable scientific obstacles that confront development
of an effective AIDS vaccine. They will also have learned of critical questions
currently facing the field, particularly with respect to the degree of emphasis
that should be placed on discovery research versus product development and
clinical testing.
a Tuesday, 12 noon-12:30 pm; Auditorium
Session 25–Plenary CME
AIDS Vaccine at the Crossroads
92
Neal Nathanson
Univ of Pennsylvania Med Ctr, Philadelphia, US
Objectives: This session is directed to clinicians and scientists interested
in the status of AIDS vaccine development. It is assumed that participants
are familiar with HIV infection and the pathogenesis of AIDS, and with the
history of attempts to develop an AIDS vaccine, as well as the general basis
of vaccines against other viral infections. At the completion of the session,
the participants will be knowledgeable about some of the problems with
development of an AIDS vaccine. Also, they will be acquainted with some
of the proposed strategies to make a more effective candidate immunogen to
protect against HIV infection.
Program 13
Tuesday
February 5 Sessions